Novel flavivirus antigens
Details for Australian Patent Application No. 2003267943 (hide)
International Classifications
Event Publications
8 January 2004 Complete Application Filed
Priority application(s): 60/360,030 26.02.02 US
12 February 2004 Application Open to Public Inspection
Published as AU-B-2003267943
6 January 2005 Section 223 Application Allowed
MAXYGEN, INC. The time in which to enter the National Phase has been extended to 26 Oct 2004. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000 2004
16 October 2008 Application Accepted
Published as AU-B-2003267943
15 January 2009 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 15 Dec 2008. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000
21 May 2009 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 15 Dec 2008
21 May 2009 Standard Patent Sealed
3 November 2011 Assignment Registered
Maxygen, Inc. The patent has been assigned to AltraVax, Inc.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003267944-NOVEL TRIFLUOROMETHYLEPINEPHRINE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser